The full concept is above. A few additional points worth highlighting:

Why photoacoustics is the secret weapon here: It uses the same UST ring array as a detector, so you get optical chemistry + acoustic anatomy from one hardware platform. This keeps cost down and co-registration trivial.

The wearable patch extension is the sleeper business: A disposable NIRS patch worn post-hip/knee replacement (30-day wear, transmits to phone app) is a SaaS-friendly product that could generate recurring revenue far larger than capital equipment sales. DVT prophylaxis monitoring is a $900M+ market that is currently served only by clinical visits.

Biggest technical bet to validate early: Whether DOS/NIRS can distinguish a fibrin-rich thrombus from slow-flowing venous blood in a phantom before committing to human studies. This is a 6-month bench experiment that de-risks the whole platform.

Want me to go deeper on any specific aspect - the signal processing architecture, the clinical trial design, the patent claims strategy, or the pitch deck structure?